<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During the last few years the use of intravenous immunoglobulin (IVIG) has attracted increasing interest for the treatment of patients who do not have a classical humoral <z:e sem="disease" ids="C0003257" disease_type="Disease or Syndrome" abbrv="">antibody deficiency syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In certain situations this approach has revolutionized medical management, e.g. in <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In other areas, such as in <z:e sem="disease" ids="C0026691" disease_type="Disease or Syndrome" abbrv="MLNS|MCLS">Kawasaki's syndrome</z:e>, IVIG therapy have been shown to be highly beneficial in preventing long term disease sequelae by some investigators, but the field remains controversial </plain></SENT>
<SENT sid="3" pm="."><plain>Conditions under which IVIG therapy has been shown to be of potential benefit are: (1) intractable childhood <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>; (2) <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, e.g. <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo>, idiopathic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>; (3) <z:e sem="disease" ids="C0392707,C1706410" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">atopic allergy</z:e> with <z:e sem="disease" ids="C0162539" disease_type="Disease or Syndrome" abbrv="">IgG subclass deficiency</z:e> including <z:hpo ids='HP_0002099'>bronchial asthma</z:hpo>; (4) in severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in combination therapy with antibiotics and as an <z:chebi fb="0" ids="35493">antipyretic</z:chebi>; (5) in <z:e sem="disease" ids="C0026691" disease_type="Disease or Syndrome" abbrv="MLNS|MCLS">Kawasaki's disease</z:e>; (6) in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Oral and intraventricular administration of IVIG have also been tried, the former for severe <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and the latter to try to rescue the central <z:mp ids='MP_0008912'>nervous</z:mp> system from damage by a pathogen </plain></SENT>
<SENT sid="5" pm="."><plain>Carefully controlled clinical trials are needed to establish the efficacy of gamma-globulin therapy in these and other conditions </plain></SENT>
</text></document>